Evidence map›Paper›PMID 35216271›Full record

ArticleInternational journal of molecular sciences2022

Detection of Pathological Markers of Neurodegenerative Diseases following Microfluidic Direct Conversion of Patient Fibroblasts into Neurons.

Cristiana Mollinari, Chiara De Dominicis, Leonardo Lupacchini, Luigi Sansone, Davide Caprini, Carlo Massimo Casciola, Ying Wang, Jian Zhao, Massimo Fini, Matteo Russo and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Cristiana MollinariDepartment of Neuroscience, Istituto Superiore di Sanita', 00161 Rome, Italy.
Chiara De DominicisDepartment of Neuroscience, Istituto Superiore di Sanita', 00161 Rome, Italy.
Leonardo LupacchiniIRCCS San Raffaele Roma, 00163 Rome, Italy.
Luigi SansoneIRCCS San Raffaele Roma, 00163 Rome, Italy.ORCID 0000-0003-3150-6461
Davide CapriniCenter for Life Nano and Neuro Sciences (CLN2S@Sapienza), Istituto Italiano di Tecnologia, 00161 Rome, Italy.ORCID 0000-0003-3041-9630
Carlo Massimo CasciolaDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00184 Roma, Italy.
Ying WangLab of Regenerative Medicine and Neural Repair, Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Jian ZhaoLab of Regenerative Medicine and Neural Repair, Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0002-8862-0591
Massimo FiniIRCCS San Raffaele Roma, 00163 Rome, Italy.
Matteo RussoIRCCS San Raffaele Roma, 00163 Rome, Italy.ORCID 0000-0002-5847-6015
Enrico GaraciIRCCS San Raffaele Roma, 00163 Rome, Italy.
Daniela MerloDepartment of Neuroscience, Istituto Superiore di Sanita', 00161 Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Superiore di Sanità · ITSan Raffaele University of Rome · ITShanghaiTech University · CNItalian Institute of Technology · ITSapienza University of Rome · IT

Funding

Istituto Superiore di Sanità Bando di ricerca indipendente dell'Istituto Superiore di Sanità 2021
6 · The paper itself

Abstract

Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease are clinically diagnosed using neuropsychological and cognitive tests, expensive neuroimaging-based approaches (MRI and PET) and invasive and time-consuming lumbar puncture for cerebrospinal fluid (CSF) sample collection to detect biomarkers. Thus, a rapid, simple and cost-effective approach to more easily access fluids and tissues is in great need. Here, we exploit the chemical direct reprogramming of patient skin fibroblasts into neurons (chemically induced neurons, ciNs) as a novel strategy for the rapid detection of different pathological markers of neurodegenerative diseases. We found that FAD fibroblasts have a reduced efficiency of reprogramming, and converted ciNs show a less complex neuronal network. In addition, ciNs from patients show misfolded protein accumulation and mitochondria ultrastructural abnormalities, biomarkers commonly associated with neurodegeneration. Moreover, for the first time, we show that microfluidic technology, in combination with chemical reprogramming, enables on-chip examination of disease pathological processes and may have important applications in diagnosis. In conclusion, ciNs on microfluidic devices represent a small-scale, non-invasive and cost-effective high-throughput tool for protein misfolding disease diagnosis and may be useful for new biomarker discovery, disease mechanism studies and design of personalised therapies.

Indexed as

AdolescentAdultAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionFemaleFibroblastsHumansLab-On-A-Chip DevicesMaleMicrofluidicsMiddle AgedNeurodegenerative DiseasesAmyloid beta-PeptidesBiomarkersbiomarkersinduced neuronsmicrofluidicsneurodegenerationtransdifferentiation

Identifiers

PMID35216271
PMCPMC8879457
OpenAlexW4212895598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.